X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare IPCA Labs with ALEMBIC LTD - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs ALEMBIC LTD - Comparison Results

IPCA LABS    Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

ALEMBIC LTD 
   Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS ALEMBIC LTD IPCA LABS/
ALEMBIC LTD
 
P/E (TTM) x 29.7 58.4 50.9% View Chart
P/BV x 3.5 2.4 144.5% View Chart
Dividend Yield % 0.1 0.4 31.8%  

Financials

 IPCA LABS   ALEMBIC LTD
EQUITY SHARE DATA
    IPCA LABS
Mar-18
ALEMBIC LTD
Mar-18
IPCA LABS/
ALEMBIC LTD
5-Yr Chart
Click to enlarge
High Rs69572 965.8%   
Low Rs40034 1,179.9%   
Sales per share (Unadj.) Rs260.24.7 5,535.2%  
Earnings per share (Unadj.) Rs19.06.1 310.8%  
Cash flow per share (Unadj.) Rs33.16.2 529.3%  
Dividends per share (Unadj.) Rs1.000.20 500.0%  
Dividend yield (eoy) %0.20.4 48.3%  
Book value per share (Unadj.) Rs213.040.7 523.9%  
Shares outstanding (eoy) m126.20267.03 47.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.111.3 18.7%   
Avg P/E ratio x28.98.7 332.8%  
P/CF ratio (eoy) x16.68.5 195.4%  
Price / Book Value ratio x2.61.3 197.4%  
Dividend payout %5.33.3 160.9%   
Avg Mkt Cap Rs m69,12014,139 488.9%   
No. of employees `00013.3NA-   
Total wages/salary Rs m7,359207 3,548.1%   
Avg. sales/employee Rs Th2,477.4NM-  
Avg. wages/employee Rs Th555.2NM-  
Avg. net profit/employee Rs Th180.6NM-  
INCOME DATA
Net Sales Rs m32,8361,255 2,616.0%  
Other income Rs m418370 112.9%   
Total revenues Rs m33,2541,625 2,045.9%   
Gross profit Rs m4,505111 4,054.7%  
Depreciation Rs m1,77738 4,701.9%   
Interest Rs m2402 14,129.4%   
Profit before tax Rs m2,905442 657.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m01,212 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m51124 2,134.0%   
Profit after tax Rs m2,3941,630 146.9%  
Gross profit margin %13.78.9 155.0%  
Effective tax rate %17.65.4 324.5%   
Net profit margin %7.3129.8 5.6%  
BALANCE SHEET DATA
Current assets Rs m19,4551,867 1,042.0%   
Current liabilities Rs m10,076591 1,704.3%   
Net working cap to sales %28.6101.6 28.1%  
Current ratio x1.93.2 61.1%  
Inventory Days Days9894 103.9%  
Debtors Days Days6774 91.0%  
Net fixed assets Rs m20,2601,791 1,131.3%   
Share capital Rs m252534 47.3%   
"Free" reserves Rs m26,63310,324 258.0%   
Net worth Rs m26,88610,858 247.6%   
Long term debt Rs m2,34041 5,679.9%   
Total assets Rs m41,17311,591 355.2%  
Interest coverage x13.1260.9 5.0%   
Debt to equity ratio x0.10 2,293.8%  
Sales to assets ratio x0.80.1 736.4%   
Return on assets %6.414.1 45.5%  
Return on equity %8.915.0 59.3%  
Return on capital %10.815.2 70.9%  
Exports to sales %47.61.5 3,082.2%   
Imports to sales %14.921.0 70.9%   
Exports (fob) Rs m15,64219 80,629.4%   
Imports (cif) Rs m4,884263 1,854.5%   
Fx inflow Rs m15,64219 80,629.4%   
Fx outflow Rs m4,884264 1,851.1%   
Net fx Rs m10,759-244 -4,401.6%   
CASH FLOW
From Operations Rs m3,411236 1,446.7%  
From Investments Rs m-1,354-224 604.5%  
From Financial Activity Rs m-1,304-27 4,902.6%  
Net Cashflow Rs m753-15 -5,089.2%  

Share Holding

Indian Promoters % 45.9 64.0 71.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.4 0.2 5,700.0%  
FIIs % 25.3 9.7 260.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 26.1 66.7%  
Shareholders   36,892 54,701 67.4%  
Pledged promoter(s) holding % 2.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   AJANTA PHARMA  GLENMARK PHARMA  SUN PHARMA  FRESENIUS KABI ONCO.  FDC LTD.  

Compare IPCA LABS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 170 Points Lower, Realty and FMCG Stocks Witness Selling(Closing)

After opening the day on a positive note, share markets in India witnessed volatile trading activity and ended in red.

Related Views on News

IPCA LABS Announces Quarterly Results (1QFY19); Net Profit Down 423.6% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, IPCA LABS has posted a net profit of Rs 655 m (down 423.6% YoY). Sales on the other hand came in at Rs 9 bn (up 19.8% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

ALEMBIC LTD Announces Quarterly Results (1QFY19); Net Profit Up 106.9% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, ALEMBIC LTD has posted a net profit of Rs 69 m (up 106.9% YoY). Sales on the other hand came in at Rs 445 m (up 50.4% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

In a Crisis, if Petrol Prices Hit Rs 100, This Stock Could Be a Good Buy(The 5 Minute Wrapup)

Sep 6, 2018

The rise in the crude oil price is a major reason for the fall in the market. If crude oil prices keep on rising, what will happen to stocks?

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

Hurricanes Threaten Oil Spike, but the Saudis are Selling...(Vivek Kaul's Diary)

Sep 6, 2018

Oil prices are rising and could go even more higher amid rising tensions in Middle East.

Should You Be Worried About the Rising Dollar?(Chart Of The Day)

Sep 7, 2018

While the rupee has deprecated by about 5% annually since 1990 against the dollar, the BSE Sensex has returned 14% annually in the same period.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Sep 19, 2018 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS - SANOFI INDIA COMPARISON

COMPARE IPCA LABS WITH

MARKET STATS